The company continues to build validation data and believes its lower cost proposition can help it gain leverage in the European market where molecular tests are not reimbursed.
Frontotemporal dementia (FTD) often strikes our most human traits, such as the ability to speak and to interact on social and emotional levels. Now, research led by Lorenzo Pasquini and William Seeley ...